The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
about
Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
P2860
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
@ast
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
@en
type
label
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
@ast
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
@en
prefLabel
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
@ast
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
@en
P2093
P2860
P921
P1476
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
@en
P2093
Anuj Mahindra
Constantine S Mitsiades
Irene M Ghobrial
Jacalyn Rosenblatt
Jacob P Laubach
Nikhil Munshi
Noopur Raje
Robert L Schlossman
P2860
P356
10.1111/J.1600-0609.2011.01721.X
P5008
P577
2011-11-22T00:00:00Z
2012-01-01T00:00:00Z